The Tool Desk
Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →There is no evidence-based five-year price target for GRAIL (Nasdaq: GRAL) in the available figures. The company’s prospects hinge on whether it can turn Galleri’s test sales into sustained, reimbursed demand, secure a favorable final FDA decision, and reduce cash losses without excessive dilution. As of October 4, 2026, analyst estimates cited by The Motley Fool projected revenue growth through 2030 but still negative free cash flow that year; those estimates are not company guidance or a share-price forecast.
What the 171% rally does—and does not—say
The Motley Fool reported that GRAIL shares had risen 171% over the six months to October 4, 2026. Its market snapshot showed a $143.26 share quote and a 52-week range of $41.50 to $151.46. Those figures describe a dated market move, not a forecast of the company’s operating performance or its stock price five years later.
A sharp gain can raise the stakes for an investor: future returns depend not only on whether GRAIL grows, but also on how much optimism is already reflected in the price, how much capital the business needs, and how the share count changes. The cited material does not establish a suitable valuation multiple or a five-year target price.
What analysts expect by 2030
Visible Alpha consensus figures reported by The Motley Fool show a path to higher revenue alongside continuing cash burn. They are analyst estimates, not GRAIL guidance, and they stop at 2030 rather than providing a five-year share-price target.
Recommended Free Tools
#1 Best Overall
- KG2 Stock Certificate
- Green Border
- pack of 15
| Measure | 2026 estimate | 2030 estimate | How to read it |
|---|---|---|---|
| Revenue | $180.7 million | $498.9 million | Analyst consensus reported by The Motley Fool on October 4, 2026; not company guidance. |
| Free cash flow | −$244.8 million | −$50.7 million | Analyst consensus reported by The Motley Fool on October 4, 2026; still negative in 2030. |
The estimates imply substantial improvement in free cash flow, but not that the business reaches cash-flow break-even by 2030. Even if revenue approaches the estimate, shareholder returns would still depend on margins, cash needs, dilution, and the valuation investors assign to future results.
Galleri is the central growth bet
Commercial traction
GRAIL said it had sold more than 595,000 commercial Galleri tests through June 30, 2026, including more than 117,000 in the first half of that year. Those sales indicate that the test has found commercial demand, but test volume alone does not show whether customers will repeat testing, whether clinicians will adopt it broadly, what net price GRAIL receives, or whether insurers will pay.
Rank #2
- Item Trademark: EXHIBITINDEXESCOM
- Item Category: Office Products
- Manufacturer: exhibitindexes
- Manufacturer: exhibitindexes
Clinical results require context
Galleri is a blood test designed to detect cancer-associated DNA signals and predict a likely origin for the signal. In its June 30, 2026 quarterly filing, GRAIL described PATHFINDER 2 and the NHS-Galleri study. The company said the test was associated with increased early-stage detection and fewer cancer diagnoses following emergency presentation, within the study contexts it reported.
The NHS-Galleri study’s prespecified primary endpoint was not met: it did not observe a statistically significant reduction in combined stage III and IV diagnoses for the designated group of 12 cancers. GRAIL’s report, as quoted by The Motley Fool, stated: “The primary endpoint of statistically significant Stage III-IV reduction was not observed”. Favorable secondary findings do not erase that primary-endpoint result.
Rank #3
- ✨ ELEGANT WHITE DESIGN: Create stunning award certificates with our premium white certificate paper. The ornate border on bright white certificate paper gives a prestigious look to every award you present.
- 🛡️ SUPERIOR HEAVYWEIGHT CARDSTOCK: Our thick 180 GSM certificate cardstock paper offers a premium feel. This sturdy diploma paper resists bending, ensuring your diploma certificate or award looks professional and impressive.
- ✅ FLAWLESS PRINTER PERFORMANCE: This certificate paper 8.5 x 11 for printing is designed for both inkjet & laser printers. Our high-quality paper ensures smudge-free, professional results for every certificate you create.
- ♾️ VERSATILE FOR ANY OCCASION: Perfect as blank certificate paper for custom awards. Create professional award paper certificates for graduations, promotions, or any special recognition. Ideal for all your certificate needs.
- ⭐ IDEAL FOR EVERY ACHIEVEMENT: From a diploma certificate, graduation certificates to award paper certificates, our cardstock certificate paper is the perfect choice. This blank certificate paper ensures every award has a premium and memorable feel.
Reported test metrics are not one general “accuracy” score
The Motley Fool reproduced figures attributed to GRAIL presentations. Episode sensitivity is the share of cancer episodes identified under the relevant study definition; positive predictive value is the share of positive results that correspond to cancer; specificity concerns negative results among people without cancer; and cancer-signal-origin accuracy concerns whether the predicted origin is correct. These are distinct measures with different denominators. The cited summary does not establish that the two studies used directly comparable populations or measurement contexts, so the figures should not be read as a head-to-head comparison.
| Reported measure | NHS-Galleri | PATHFINDER 2 |
|---|---|---|
| Episode sensitivity | 30.7% overall; 54.7% for the 12 deadly cancers | 39.3% overall; 69.8% for the 12 deadly cancers |
| Positive predictive value | 52% | 60.3% |
| Specificity | 99.6% | 99.6% |
| Cancer-signal-origin accuracy | 92.5% | 85% |
These figures are attributed to GRAIL presentations as reproduced by The Motley Fool; they are not a substitute for a final regulatory assessment or proof of clinical utility in routine screening. A positive result can prompt additional testing, and false-positive follow-up carries clinical, financial, and practical costs. How those trade-offs affect physicians and patients will matter to adoption and coverage.
Rank #4
- Green-inked border design
- Large centered Eagle Symbol
- Contains space for company name, authorized stock structure, delegated shareholder, and date (see Product Description for Custom Printing reference)
- 15 individual corporate stock certificates
- 3 punched holes on top of each item for simple insertion into binders
FDA review is a catalyst, not the finish line
GRAIL’s June 2026 filing said its premarket approval (PMA) application, submitted in January 2026, had been accepted for FDA review. The Motley Fool reported that an FDA advisory panel voted favorably on Galleri’s safety, benefit, and effectiveness. An advisory panel’s recommendation is not the FDA’s final approval decision. A final decision, the permitted labeling, and any post-market requirements can shape how the test may be used and marketed.
Regulatory clearance or approval would not by itself guarantee a large business. Clinicians must see sufficient value in ordering the test, patients must be willing and able to pay where coverage is absent, and public or private payers must decide whether evidence justifies reimbursement. Coverage policies, test pricing, and follow-up costs therefore remain separate commercial hurdles.
Free tools Windows power users keep installed
One-click scans. No signup required.
Best Value
What could make the five-year case stronger or weaker
| Driver | What would strengthen the case | What would weaken it |
|---|---|---|
| Clinical and regulatory | A favorable final FDA decision, workable labeling, and further evidence supporting clinical utility. | An unfavorable or delayed decision, restrictive labeling, unresolved evidence questions, or costly post-market requirements. |
| Commercial adoption | Growing test volume, repeat use, clinician uptake, and payer coverage at sustainable pricing. | Slow uptake, limited coverage, pressure on realized price, or high costs from positive-result follow-up. |
| Cash generation | Revenue growth translating into improved margins and cash flow faster than expected. | Operating costs and investment needs remaining high as revenue grows, extending cash burn. |
| Share count and execution | Commercial expansion funded on terms that limit dilution and partnerships delivering measurable sales. | Equity issuance diluting existing holders, execution setbacks, or meaningful share sales adding supply. |
| Valuation | Future cash flows supporting the price investors pay today. | Expectations outrunning evidence, or a lower market valuation for uncertain long-term revenue. |
Capital needs and dilution belong in the thesis
GRAIL’s fiscal 2025 Form 10-K disclosed an at-the-market (ATM) equity program of up to $300 million or 6.9 million shares, with $189.3 million of capacity remaining as of December 31, 2025. That is dated financing capacity, not evidence that the remaining amount was later issued. If shares are sold, the company can raise capital, but existing shareholders may own a smaller proportion of the business.
The same filing described an intended exclusive Samsung C&T collaboration to commercialize Galleri in Korea and potentially other Asian markets, subject to execution and applicable conditions. It also noted that Illumina’s retained shares could be sold and that significant sales could pressure GRAIL’s stock. The partnership is a potential route to wider commercialization, not proof of realized sales; potential share sales are a supply risk, not a prediction that they will occur.
How to assess GRAL without pretending to know its 2031 price
- Separate business evidence from share performance. The six-month rally is a market snapshot; evaluate test sales, clinical evidence, regulatory progress, and cash use independently.
- Track conversion, not just volume. Follow reported test sales alongside pricing, repeat use, payer decisions, and whether commercial growth improves cash generation.
- Watch the FDA decision and its terms. A panel vote and application review are milestones, not a final decision or a guarantee of reimbursement.
- Revisit financing and dilution. Compare later filings with the 2025 ATM disclosure and monitor whether capital raises or other share supply change the per-share outlook.
- Use scenarios rather than a point target. A bullish case needs adoption, coverage, and economics to develop favorably; a bearish case can follow from weak uptake, clinical or regulatory setbacks, persistent cash burn, or dilution. The available consensus estimates alone cannot determine a future share price.
For a five-year investor, GRAIL is best viewed as a high-uncertainty commercial and regulatory execution story, not as a stock with a defensible price destination already established. The key question is whether evidence, reimbursement, and cash economics catch up with the expectations reflected in the share price.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
